EAU guidelines on prostate cancer

G Aus, CC Abbou, M Bolla, A Heidenreich, HP Schmid… - European urology, 2005 - Elsevier
OBJECTIVES:: The first summary of the European Association of Urology (EAU) guidelines
on prostate cancer was published in 2001. These guidelines have been continuously …

[HTML][HTML] Androgen deprivation therapy in the treatment of advanced prostate cancer

MA Perlmutter, H Lepor - Reviews in urology, 2007 - ncbi.nlm.nih.gov
This article reviews the issues and controversies relevant to the treatment of advanced
prostate cancer with androgen deprivation therapy. Initially, diethylstilbestrol was used for …

[PDF][PDF] Guidelines on

A Heidenreich, M Bolla, S Joniau, MD Mason… - Update, 2007 - imop.med.auth.gr
The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have
prepared this guidelines document to assist medical professionals assess the evidence …

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)

EJ Small, S Halabi, NA Dawson, WM Stadler… - Journal of clinical …, 2004 - ascopubs.org
Purpose Antiandrogen withdrawal (AAWD) results in a prostate-specific antigen (PSA)
response (decline in PSA level of≥ 50%) in 15% to 30% of androgen-independent prostate …

Mechanisms mediating androgen receptor reactivation after castration

X Yuan, SP Balk - Urologic Oncology: Seminars and Original …, 2009 - Elsevier
Androgen deprivation is still the standard systemic therapy for metastatic prostate cancer
(PCa), but patients invariably relapse with a more aggressive form of PCa termed hormone …

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

EJ Small, NJ Vogelzang - Journal of Clinical Oncology, 1997 - ascopubs.org
PURPOSE To discuss the evolution of new concepts in the Use of second-line hormonal
therapy for patients with progressive prostate cancer despite androgen deprivation. DESIGN …

Secondary hormonal therapy for advanced prostate cancer

JS Lam, JT Leppert, SN Vemulapalli, O Shvarts… - The Journal of …, 2006 - Elsevier
PURPOSE: Androgen ablation remains the cornerstone of management for advanced
prostate cancer. Therapeutic options in patients with progressive disease following …

[HTML][HTML] Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones

M Marklund, N Schultz, S Friedrich, E Berglund… - Nature …, 2022 - nature.com
The molecular mechanisms underlying lethal castration-resistant prostate cancer remain
poorly understood, with intratumoral heterogeneity a likely contributing factor. To examine …

Current strategies in the management of hormone refractory prostate cancer

CL Martel, PH Gumerlock, FJ Meyers… - Cancer Treatment …, 2003 - Elsevier
Prostate cancer is the most common cancer diagnosed in American males, and is the
second leading cause of cancer-related deaths. Most patients who develop metastatic …

Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment

A Anantharaman, EJ Small - Expert review of anticancer therapy, 2017 - Taylor & Francis
ABSTRACT Introduction: Prostate cancer (PCa) is currently the second most common
cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is …